Incyte Corporation (LON:0J9P)

Market Cap	14.42B
Revenue (ttm)	3.58B +18.1%
Net Income	884.23M +3,559.2%
EPS	4.39 +3,878.0%
Shares Out	n/a
PE Ratio	16.31
Forward PE	12.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166
Average Volume	3,055
Open	103.10
Previous Close	100.80
Day's Range	100.13 - 103.41
52-Week Range	53.61 - 112.60
Beta	0.82
RSI	44.61
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,617
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J9P

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD